SUNY Distinguished Professor and Chair, Department of Pharmaceutical Sciences University at Buffalo, State University of New York Buffalo, New York
Transporter-related proteins encompass about 10% of human genes, highlighting their biological relevance. They include the SoLute Carrier (SLC) transporters superfamily, ATP-binding cassette (ABC) transporters, channels and pumps. They play pivotal roles in the absorption, distribution and excretion of xenobiotic and endogenous molecules. Despite growth of the field of transporter biology, more than half of the members of transporter families have little information available about their endogenous substrate(s) or physiological functions. Transporter biochemistry is now revealing emerging roles for these membrane proteins and selected transporter proteins are being implicated in important pathological events such as oncogenesis. This has been reported for monocarboxylate, amino acid, iodide, and nucleoside transporters, among others. Other novel functions of transporters reported include the role of OCT1 in thiamine uptake in the liver and the association with non-alcoholic fatty liver disease; the protection of mice from high-fat diet induced obesity and insulin resistance associated with the loss of the citrate transporter Slc13a5; the involvement of zinc transporters ZnT8 in the regulation of the insulin pathway in the pancreas and liver. Transporter biology is a rapidly changing field in pharmaceutical research. Many drugs, nutrients and metabolites undergo facilitated or active transport not only through the plasma membrane but also among subcellular organelles including the endoplasmic reticulum, lysosomes and mitochondria. Thus, transport proteins remain one of the most underestimated fields for drug targets. This symposium will address specific examples of transporters as novel therapeutic targets for the treatment of disease.
• Upon completion, participants will be able to identify SLC and ABC transporters that may have novel roles in physiology and disease.
• Upon completion, participants will be able to understand the potential roles of monocarboxylate transporters (SLC16) as therapeutic targets
• Upon completion, participants will be familar with the upcoming presentations in this symposium